In:
British Journal of Haematology, Wiley, Vol. 169, No. 1 ( 2015-04), p. 90-102
Abstract:
Children with B cell malignancies refractory to standard therapy are known to have a poor prognosis and very limited treatment options. Here, we report on the treatment and follow‐up of ten patients diagnosed with relapsed or refractory mature B‐cell Non Hodgkin Lymphoma (B‐ NHL ), Burkitt leukaemia (B‐ AL ) or pre B‐acute lymphoblastic leukaemia (pre B‐ ALL ). All children were treated with FBTA 05 (now designated Lymphomun), an anti‐ CD 3 x anti‐ CD 20 trifunctional bispecific antibody (trAb) in compassionate use. Within individual treatment schedules, Lymphomun was applied (a) after allogeneic stem cell transplantation (allo‐ SCT , n = 6) to induce sustained long‐term remission, or (b) stand alone prior to subsequent chemotherapy to eradicate residual disease before allo‐ SCT ( n = 4). Nine of ten children displayed a clinical response: three stable diseases ( SD ), one partial remission ( PR ) and five induced or sustained complete remissions ( CR ). Five of these nine responders died during follow‐up. The other patients still maintain CR with a current overall survival of 874–1424 days (median: 1150 days). In conclusion, despite the dismal clinical prognosis of children refractory to standard therapy, immunotherapy with Lymphomun resulted in a favourable clinical outcome in this cohort of refractory paediatric patients.
Type of Medium:
Online Resource
ISSN:
0007-1048
,
1365-2141
DOI:
10.1111/bjh.2015.169.issue-1
Language:
English
Publisher:
Wiley
Publication Date:
2015
detail.hit.zdb_id:
1475751-5